(Total Views: 113)
Posted On: 09/16/2024 4:59:42 PM
Post# of 94
NetworkNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Schedules Virtual Panel Discussion on Plaque Psoriasis, Its Promising Novel Solution
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit, today announced plans to host a scientific webinar to discuss the plaque psoriasis landscape, current treatment methods, and existing unmet needs in treating mild to moderate plaque psoriasis. The virtual panel discussion will also explore intralesional injections of the company’s novel anti-IL-17A/F VHH single domain VHH antibodies as a promising solution. Other topics will include an introduction to single domain VHH antibodies and the company’s pipeline, with panelists also reviewing the biological drug development journey toward marketing authorization. The webinar is scheduled for Wednesday, September 18, 2024, at 11 a.m. EDT/ 6 p.m. Israel time.
NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://nnw.fm/SCNI
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit, today announced plans to host a scientific webinar to discuss the plaque psoriasis landscape, current treatment methods, and existing unmet needs in treating mild to moderate plaque psoriasis. The virtual panel discussion will also explore intralesional injections of the company’s novel anti-IL-17A/F VHH single domain VHH antibodies as a promising solution. Other topics will include an introduction to single domain VHH antibodies and the company’s pipeline, with panelists also reviewing the biological drug development journey toward marketing authorization. The webinar is scheduled for Wednesday, September 18, 2024, at 11 a.m. EDT/ 6 p.m. Israel time.
NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://nnw.fm/SCNI
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)
